Fuzeon Sales Message: All Patients Benefit, But "The Earlier The Better"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche is emphasizing the benefit of early administration of its HIV therapy Fuzeon.
You may also be interested in...
Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks
Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.
Fuzeon Increased Pneumonia Incidence Likely A "Specious" Finding – FDA
The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.
Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks
Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.